S

Shanghai OPM Biosciences Co Ltd
SSE:688293

Watchlist Manager
Shanghai OPM Biosciences Co Ltd
SSE:688293
Watchlist
Price: 51.68 CNY 0.23%
Market Cap: 5.9B CNY

Shanghai OPM Biosciences Co Ltd
Operating Income

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Shanghai OPM Biosciences Co Ltd
Operating Income Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Operating Income CAGR 3Y CAGR 5Y CAGR 10Y
S
Shanghai OPM Biosciences Co Ltd
SSE:688293
Operating Income
ÂĄ11.5m
CAGR 3-Years
-42%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Beigene Ltd
HKEX:6160
Operating Income
-ÂĄ4.2B
CAGR 3-Years
23%
CAGR 5-Years
9%
CAGR 10-Years
N/A
Innovent Biologics Inc
HKEX:1801
Operating Income
ÂĄ1.4B
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Akeso Inc
HKEX:9926
Operating Income
-ÂĄ675.3m
CAGR 3-Years
19%
CAGR 5-Years
-14%
CAGR 10-Years
N/A
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
Operating Income
-ÂĄ119m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
S
Sichuan Kelun-Biotech Biopharmaceutical Co Ltd
HKEX:6990
Operating Income
-ÂĄ212.1m
CAGR 3-Years
36%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Shanghai OPM Biosciences Co Ltd
Glance View

Market Cap
5.9B CNY
Industry
Biotechnology

Shanghai OPM Biosciences Co. Ltd. engages in the cell culture products and services. The company is headquartered in Shanghai, Shanghai and currently employs 261 full-time employees. The company went IPO on 2022-09-02. The firm's cell culture medium products are widely used in the manufacturing of protein, antibiotics, vaccine, cell therapy products, gene therapy products, and other biological products. The firm's contract development and manufacturing organization (CDMO) service platform provides comprehensive services covering antibody engineering humanized screening, cell strain cultivation, process development, pilot scale production, and clinical-stage sample production. The firm conducts businesses both in the domestic market and overseas markets.

Intrinsic Value
46.03 CNY
Overvaluation 11%
Intrinsic Value
Price
S

See Also

What is Shanghai OPM Biosciences Co Ltd's Operating Income?
Operating Income
11.5m CNY

Based on the financial report for Dec 31, 2024, Shanghai OPM Biosciences Co Ltd's Operating Income amounts to 11.5m CNY.

What is Shanghai OPM Biosciences Co Ltd's Operating Income growth rate?
Operating Income CAGR 3Y
-42%

Over the last year, the Operating Income growth was -56%. The average annual Operating Income growth rates for Shanghai OPM Biosciences Co Ltd have been -42% over the past three years .

Back to Top